Mortality and Morbidity Results from the European Working Party on High Blood Pressure in the Elderly Trial
Mortality and Morbidity Results from the European Working Party on High Blood Pressure in the Elderly Trial
复制标题
欧洲老年人高血压工作组试验的死亡率和发病率结果
DOI：
--
复制
发表时间：
1985
期刊：
影响因子：
--
通讯作者：
C. Bulpitt
中科院分区：
文献类型：
--
作者：
C. Bulpitt
后者是由于心脏死亡率的降低(−38%，p=0.036)和脑血管死亡率的不显著降低(−32%，p=0.16)。在试验的双盲部分，总死亡率没有显著降低(−为26%，p=0.077)。然而，积极治疗组的心血管死亡率降低了(−38%，p=0.023)，这是由于心源性死亡的减少(−47%，p=0.048)和脑血管死亡率的非显著降低(−43%，p=0.048)。通过积极的治疗，心肌梗死的死亡率降低(−60%，p=0.043)，终止研究的病态心血管事件显著减少(−60%，p=0.0064)。非终末性脑血管事件减少(−52%，p=0.026)，但非终末性心脏事件未减少(+3%，p=0.98)。在随机接受积极治疗的患者中，在试验的双盲部分，每1000人年心血管事件减少29例，心血管死亡减少14例。抗高血压治疗的双盲随机安慰剂对照试验在60岁以上的患者中进行。入选标准包括安慰剂治疗时的坐位舒张压在90到119毫米汞柱之间，以及收缩压在160到239毫米之间。840名患者被随机分为两组，一组是积极治疗(氢氯噻嗪和氨甲喋呤)，另一组是与之匹配的安慰剂。如果血压持续升高，安慰剂组在有效方案中加入甲基多巴，并与之匹配的安慰剂加入。结合试验的双盲部分和所有随后的随访进行的总体意向治疗分析显示，总死亡率没有显著变化(−9%，p=0.41)，但心血管死亡率显著降低(−27%，p=0.037)。
SummaryThe latter was due to a reduction in cardiac mortality (−38%, p=0.036) and a nonsignificant decrease in cerebrovascular mortality (−32%, p=0.16). In the double-blind part of the trial, the total mortality rate was not significantly reduced (−26%, p=0.077). However, cardiovascular mortality was reduced in the actively treated group (−38%, p=0.023), owing to a reduction in cardiac deaths (−47%, p=0.048) and a non-significant decrease in cerebrovascular mortality (−43%, p=0.15). Deaths from myocardial infarction were reduced (−60%, p=0.043), and study-terminating morbid cardiovascular events were significantly reduced by active treatment (−60%, p=0.0064). Non-terminating cerebrovascular events were reduced (−52%, p=0.026), but the non-terminating cardiac events were not (+ 3%, p=0.98). In the patients randomised to active treatment there were 29 fewer cardiovascular events and 14 fewer cardiovascular deaths per 1000 patient years during the double-blind part of the trial.A double-blind randomised placebo-controlled trial of antihypertensive treatment was conducted in patients over the age of 60. Entry criteria included both a sitting diastolic blood pressure on placebo treatment in the range 90 to 119mm Hg and a systolic pressure in the range 160 to 239mm Eg. 840 patients were randomised either to active treatment (hydrochlorothiazide and triamterene) or to matching placebo. If the blood pressure remained raised, methyldopa was added to the active regimen and matching placebo in the placebo group. An overall intention-to-treat analysis, combining the double-blind part of the trial and all subsequent follow-up, revealed a non-significant change in total mortality rate (−9%, p=0.41) but a significant reduction in cardiovascular mortality rate (−27%, p=0.037).